Giada Acciaroli, United States of America
Dexcom, Inc. R&D - Data SciencePresenter of 2 Presentations
A Review of Dexcom G6 Use Around the Global
INTEGRATION OF A CGM SYSTEM AND A VOICE-CONTROLLED VIRTUAL ASSISTANT
Abstract
Background and Aims
Siri (Apple, Inc., Cupertino, CA) allows for voice control of compatible apps, including the "G6" app for a continuous glucose monitoring (CGM) system (Dexcom, Inc., San Diego, CA). A customizable voice command (by default, "Hey Siri what's my glucose?") is sufficient to generate a spoken response that includes the user's current sensor glucose value (SGV) and trend (e.g., "You're 134 and steady"). G6/Siri integration may simplify diabetes management, especially for patients with limited vision or dexterity. We examined patterns and potential implications of invoking the feature.
Methods
Data were from US-based anonymized G6 customers who invoked the feature in December 2019 and uploaded ≥30 days of CGM data in the first half of 2020 (1H2020). Non-users and routine users were defined as those with zero and those with an average of ≥1 feature invocation per day of CGM use in 1H2020. Feature invocations were analyzed for routine users; summary statistics of glycemic metrics were calculated for both groups.
Results
Of the 34,572 customers who used the feature in December 2019, 6,847 were non-users and 2,282 were routine users in 1H2020. Among routine users, the median number of daily invocations was 1.84 (IQR, 1.29-3.29) and the feature was most commonly invoked between 4PM and 6PM (Figure). Time in range (70-180 mg/dL) was lower for non-users than for routine users (57±20 vs. 62±20%, respectivey); mean±SD SGVs were 177±39 and 169±36 mg/dL, respectively.
Conclusions
Routine use of the G6/Siri integration feature may contribute to appropriate diabetes management decisions.